How Much Does Ozempic Cost in 2026? The Complete Pricing Guide for Every Insurance Situation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic costs $969 to $1,349 per month without insurance, $25 to $600 with insurance depending on formulary tier and deductible status
• The Novo Nordisk savings card reduces commercial insurance copays to $25 monthly but excludes Medicare, Medicaid, and uninsured patients
• Medicare Part D patients pay $200 to $500 monthly with no manufacturer copay assistance available
• Compounded semaglutide costs $179 to $299 monthly and becomes the cheaper option when insurance copays exceed $180 or coverage is denied

Direct answer (40-60 words)

Ozempic costs $969 to $1,349 per month at retail pharmacies without insurance in 2026. With commercial insurance, expect $25 to $600 monthly depending on your plan's formulary tier, deductible, and prior authorization requirements. Medicare patients typically pay $200 to $500 monthly. The manufacturer savings card can reduce eligible commercial copays to $25.

Table of contents

1. The pricing structure most articles misunderstand
2. Cash price breakdown by pharmacy chain (2026 data)
3. How insurance actually determines your Ozempic cost
4. Real patient cost scenarios across 8 insurance types
5. The Novo Nordisk savings card: complete eligibility rules
6. Medicare and Medicaid coverage realities
7. When compounded semaglutide costs less than brand-name Ozempic
8. The patient assistance program for low-income patients
9. Prior authorization: the hidden cost multiplier
10. The FormBlends cost decision framework
11. How to calculate your exact cost in 10 minutes
12. FAQ

The pricing structure most articles misunderstand

Most Ozempic cost articles present a single number or a vague range. This fundamentally misrepresents how pharmaceutical pricing works in the United States.

There is no single "Ozempic price." There are at least six different pricing structures operating simultaneously:

Structure 1: Wholesale acquisition cost (WAC). This is Novo Nordisk's list price to wholesalers, currently $968.52 per pen as of Q1 2026 (Novo Nordisk pricing database, 2026). No patient pays this price directly.

Structure 2: Pharmacy cash price. Each pharmacy chain sets its own markup over acquisition cost. This ranges from $969 at Costco to $1,349 at some independent pharmacies.

Structure 3: Insurance negotiated rate. Your insurance company negotiates a rate with the pharmacy, typically 15% to 30% below cash price. You never see this number, but it determines your coinsurance percentage.

Structure 4: Your formulary tier copay. Your plan assigns Ozempic to a tier (usually Tier 3 or specialty tier) with a fixed copay or coinsurance percentage.

Structure 5: Manufacturer copay assistance. The Novo Nordisk savings card creates a fifth effective price by subsidizing your copay down to $25.

Structure 6: Government program pricing. Medicare Part D, Medicaid, and VA negotiate separate pricing structures with different patient cost-sharing rules.

The question "how much does Ozempic cost" has six different answers depending on which structure applies to you. Articles that give you one number are answering the wrong question.

Cash price breakdown by pharmacy chain (2026 data)

For a standard 1 mg or 2 mg Ozempic pen (4-week supply), cash prices as of April 2026:

Pharmacy chain	Cash price per pen	90-day supply	Price per day
Costco (membership required)	$969 to $1,015	$2,907 to $3,045	$34.61
Sam's Club (membership required)	$995 to $1,045	$2,985 to $3,135	$35.54
Walmart	$1,025 to $1,089	$3,075 to $3,267	$36.61
Kroger pharmacies	$1,045 to $1,125	$3,135 to $3,375	$37.32
CVS	$1,089 to $1,175	$3,267 to $3,525	$38.89
Walgreens	$1,095 to $1,189	$3,285 to $3,567	$39.11
Independent pharmacies	$1,125 to $1,349	$3,375 to $4,047	$40.18 to $48.18

The $380 spread between Costco and the highest independent pharmacy price represents a 39% difference. For a patient paying cash for 12 months, choosing Costco over a high-priced independent pharmacy saves $4,560 annually.

Warehouse clubs (Costco, Sam's Club) consistently price 15% to 25% below traditional retail chains. The membership fee ($60 to $120 annually) pays for itself within the first fill for cash-paying patients.

How insurance actually determines your Ozempic cost

Your insurance doesn't "cover" Ozempic with a single fixed copay. It processes your prescription through a multi-step calculation that produces your out-of-pocket cost.

Step 1: Formulary placement. Your plan's pharmacy benefit manager (PBM) assigns Ozempic to a formulary tier. Most commercial plans place it on Tier 3 (non-preferred brand) or Tier 4 (specialty). A minority of employer plans with strong pharmacy benefits negotiate Tier 2 (preferred brand) placement.

Tier assignment determines your cost-sharing structure:

• Tier 2: Fixed copay, typically $40 to $100
• Tier 3: Fixed copay or coinsurance, typically $75 to $200 or 25% to 40%
• Tier 4/specialty: Coinsurance only, typically 25% to 50%

Step 2: Prior authorization check. 78% of commercial plans require prior authorization for Ozempic as of 2026 (AJMC pharmacy policy survey, 2025). If your prescription lacks PA approval, the claim is rejected and you pay full cash price or wait for approval.

Step 3: Deductible application. If you haven't met your annual deductible, you pay the full negotiated rate (not the cash price, but the rate your insurance negotiated with the pharmacy, typically $750 to $950). Once your deductible is met, your tier copay or coinsurance applies.

Step 4: Manufacturer copay card processing. If you present the Novo Nordisk savings card, the pharmacy processes it after your insurance. The card pays the difference between your copay and $25, up to a maximum benefit of approximately $150 per fill.

Step 5: Out-of-pocket maximum. Once your total annual out-of-pocket spending reaches your plan's maximum (typically $3,000 to $9,100 for individual coverage), insurance pays 100% and your Ozempic cost drops to $0.

Most patients experience three different Ozempic costs in a single calendar year: full negotiated rate (pre-deductible), tier copay (post-deductible), and zero (post-out-of-pocket max).

Real patient cost scenarios across 8 insurance types

Scenario 1: Large employer PPO, Tier 2 placement. Patient works for a Fortune 100 company with comprehensive pharmacy benefits. Ozempic is Tier 2 (preferred brand). Annual deductible: $500, met in February. Copay: $50 per fill. Savings card reduces copay to $25. Annual cost: $500 (deductible) + $275 (11 months × $25) = $775.

Scenario 2: Small employer PPO, Tier 3 placement. Patient works for a 50-person company. Ozempic is Tier 3 (non-preferred brand) with 30% coinsurance. Deductible: $2,500. Negotiated rate: $850 per fill. Patient pays full $850 for first three fills ($2,550 total, meeting deductible). Remaining nine fills: 30% × $850 = $255, reduced to $105 after savings card ($150 max benefit). Annual cost: $2,550 + $945 = $3,495.

Scenario 3: Marketplace silver plan, high deductible. Patient purchased coverage through Healthcare.gov. Ozempic requires prior authorization (approved after 8-day delay). Tier 4 specialty with 40% coinsurance. Deductible: $4,500. Negotiated rate: $825. First six fills are full price ($4,950, exceeding deductible). Remaining six fills: 40% × $825 = $330, reduced to $180 after savings card. Annual cost: $4,500 (deductible) + $1,080 = $5,580.

Scenario 4: Medicare Part D, standard plan. Patient is 68, retired, enrolled in a standalone Part D plan. Ozempic for type 2 diabetes is covered on specialty tier. Copay: $280 per fill. Savings card does NOT apply to Medicare. Annual cost before coverage gap: $280 × 12 = $3,360. In coverage gap (donut hole), patient may pay 25% of total drug cost ($850 × 25% = $212.50) for 2-3 months. Total annual cost: approximately $3,100 to $3,600.

Scenario 5: Medicare Advantage with enhanced drug coverage. Patient has a Medicare Advantage plan with $0 deductible for Tier 3 drugs. Ozempic copay: $200 per fill. No savings card eligibility. Annual cost: $2,400.

Scenario 6: Medicaid (state-dependent). Patient in California with Medi-Cal coverage. Ozempic for diabetes is covered with prior authorization. Copay: $0 to $5 per fill after PA approval. Annual cost: $0 to $60. (Note: 14 states don't cover Ozempic for diabetes at all under Medicaid as of 2026.)

Scenario 7: No insurance, using GoodRx. Patient is self-employed, between coverage periods. Uses GoodRx coupon at Costco. Price: $895 per fill. Annual cost: $10,740.

Scenario 8: No insurance, switched to compounded semaglutide. Patient is self-employed, priced out of brand-name Ozempic. Switches to FormBlends compounded semaglutide at $229 per month including clinical support. Annual cost: $2,748.

The pattern across these scenarios: insurance status matters less than formulary tier, deductible structure, and savings card eligibility. A patient with "good insurance" but a high deductible and Tier 4 placement can pay more annually than an uninsured patient using compounded semaglutide.

The Novo Nordisk savings card: complete eligibility rules

The savings card is the most impactful cost-reduction tool for commercially insured patients, but eligibility rules exclude approximately 55% to 60% of Ozempic users.

Who qualifies:

• Commercial insurance (employer-sponsored or private marketplace plan) that covers Ozempic
• Prescription written for FDA-approved indication (type 2 diabetes only, not weight loss)
• U.S. resident, 18 years or older
• Not enrolled in any government-funded healthcare program

Who is explicitly excluded:

• Anyone with Medicare Part D (even if they also have commercial supplemental coverage)
• Anyone with Medicaid, TRICARE, VA benefits, or any state or federal healthcare program
• Anyone whose insurance denies coverage for Ozempic (the card reduces a copay, it doesn't create coverage)
• Anyone using Ozempic off-label for weight loss without a diabetes diagnosis
• Anyone who is uninsured

How the card works:

• Maximum benefit: $150 per fill (so if your copay is $200, you pay $50 after the card)
• Minimum copay: $25 (even if your insurance copay is $10, you'll pay $25 with the card)
• Annual limit: 13 fills per calendar year
• Lifetime limit: 24 months of eligibility from first use

Common misconceptions:

• "The savings card makes Ozempic free." No. Minimum copay is $25.
• "I can use it without insurance." No. You must have commercial insurance coverage.
• "It works with Medicare." No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries.

The card is activated at ozempic.com/savings-and-resources and presented alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your copay.

In FormBlends's clinical pattern observation, approximately 40% of patients who qualify for the savings card don't know it exists until their provider mentions it. The other 60% discover it through online research after receiving their first full-price fill.

Medicare and Medicaid coverage realities

Medicare and Medicaid represent 35% of Ozempic prescriptions for type 2 diabetes (CMS prescription data, 2025), but coverage rules differ fundamentally from commercial insurance.

Medicare Part D coverage:

• Ozempic is covered for type 2 diabetes on most Part D formularies (92% of plans as of 2026)
• Typically placed on specialty tier (Tier 4 or Tier 5)
• Copay ranges from $200 to $500 per fill depending on plan
• Prior authorization required by 68% of Part D plans
• Coverage gap (donut hole) may increase cost to 25% of total drug cost for 2-3 months mid-year
• Manufacturer savings card is prohibited by federal anti-kickback statute
• No coverage for weight loss indication under any circumstance

The Medicare Part D coverage gap creates a mid-year cost spike. A patient paying $280 per fill January through April may suddenly pay $212.50 (25% of $850) in May through July, then return to $280 in August after exiting the gap. This pattern confuses patients who assume their copay is fixed.

Medicaid coverage (state-by-state):

State Medicaid coverage tier	Number of states	Typical copay	PA required
Covered, preferred	12 states	$0 to $3	Yes, standard criteria
Covered, non-preferred	24 states	$0 to $8	Yes, strict criteria
Not covered	14 states	N/A	N/A

States that don't cover Ozempic under Medicaid as of 2026 include Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Missouri, Oklahoma, South Carolina, Tennessee, Texas, West Virginia, Wisconsin, and Wyoming (KFF Medicaid pharmacy coverage database, 2026).

Medicaid patients in non-coverage states have three options: pay cash ($969+ per month), apply for the Novo Nordisk patient assistance program if income-qualified, or switch to compounded semaglutide.

When compounded semaglutide costs less than brand-name Ozempic

The crossover point where compounded semaglutide becomes the cheaper option depends on your insurance situation.

Compounded semaglutide pricing (2026):

• FormBlends: $179 to $279 per month (includes medication, clinical oversight, and supplies)
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Cost comparison decision tree:

If your Ozempic copay with savings card is $25 to $100 per month → Brand-name Ozempic is cheaper.

If your Ozempic copay is $150 to $180 per month → Costs are approximately equal. Brand-name offers convenience of pre-filled pen. Compounded offers predictable pricing without insurance paperwork.

If your Ozempic copay exceeds $180 per month → Compounded semaglutide is meaningfully cheaper.

If you have no insurance or your insurance denies coverage → Compounded semaglutide costs 75% to 85% less than cash-price Ozempic.

If you're on Medicare Part D paying $200+ per month → Compounded semaglutide costs $80 to $150 less monthly.

The calculation most patients miss: Brand-name Ozempic cost varies month-to-month (pre-deductible vs post-deductible vs coverage gap). Compounded semaglutide cost is flat. For budgeting purposes, the predictability of compounded pricing has value beyond the dollar amount.

A patient paying $850 per fill for three months (pre-deductible), then $120 per fill for nine months (post-deductible with savings card) spends $3,630 annually on Ozempic. The same patient on compounded semaglutide at $229 monthly spends $2,748 annually and avoids the $850 monthly cost shock in January through March.

The patient assistance program for low-income patients

Novo Nordisk operates a separate program from the savings card for patients with limited financial means: the NovoCare Patient Assistance Program.

Eligibility (2026 criteria):

• Annual household income below 400% of federal poverty level ($60,240 for individual, $81,760 for couple, $124,800 for family of four)
• U.S. citizen or legal resident
• No prescription drug coverage, or coverage that denies Ozempic
• Prescription is for FDA-approved type 2 diabetes indication
• Not eligible for Medicare, Medicaid, or other government programs

What the program provides:

• Free Ozempic for up to 12 months, renewable annually
• Medication shipped directly to patient's home address
• No copay, no deductible, no out-of-pocket cost
• Includes all necessary supplies (needles not included, as Ozempic uses built-in pen needle)

Application process:

• Forms available at novocare.com/diabetes/let-us-help/pap.html
• Provider completes medical necessity section (typically 10 minutes)
• Patient completes financial disclosure section
• Supporting documents: recent tax return or pay stubs, insurance denial letter if applicable
• Processing time: 7 to 14 business days
• Approval is communicated via email and first shipment arrives 3 to 5 days later

Approval rates and patterns: The program doesn't publish approval rates, but based on FormBlends clinical pattern observation across patients we've referred to the PAP, approximately 70% of applications meeting the stated income criteria are approved on first submission. The most common denial reason is incomplete financial documentation.

The program is dramatically under-utilized. Novo Nordisk's own estimates suggest fewer than 5% of income-eligible patients apply (Novo Nordisk PAP utilization report, 2024). Most providers don't routinely mention it because the paperwork burden falls on the clinical team.

Patients who think they may qualify should explicitly ask their provider to submit a PAP application on their behalf. The 15 minutes of paperwork can eliminate $11,000+ in annual medication costs.

Prior authorization: the hidden cost multiplier

Prior authorization (PA) doesn't change the dollar amount of your copay, but it changes the effective cost by delaying treatment and creating administrative burden.

PA requirements by insurance type (2026 data):

Insurance type	% requiring PA	Average approval time	Denial rate on first submission
Commercial PPO	72%	3 to 7 business days	18%
Commercial HMO	85%	5 to 10 business days	24%
Medicare Part D	68%	7 to 14 business days	31%
Medicaid	94%	10 to 21 business days	38%
Marketplace plans	81%	5 to 12 business days	28%

(Source: AJMC prior authorization survey, 2025)

Standard PA criteria for Ozempic:

• Documented diagnosis of type 2 diabetes with HbA1c ≥ 7.0%
• Trial and failure of metformin (or documented contraindication)
• BMI ≥ 27 with comorbidity or BMI ≥ 30
• Prescription written by endocrinologist, PCP, or certified diabetes educator
• No history of medullary thyroid carcinoma or MEN2 syndrome

The cost of PA delay: A patient who receives a prescription on January 15 but doesn't receive PA approval until February 3 (19-day delay, within normal range) has delayed diabetes treatment for three weeks. If that patient was paying out-of-pocket for a different medication during the delay, the effective cost of PA is the cost of the interim medication plus the clinical risk of delayed optimal therapy.

The appeal process: When PA is denied, your provider can file a peer-to-peer appeal (a phone call between your provider and the insurance plan's medical director). Peer-to-peer appeals have a 60% to 70% success rate for Ozempic denials (AJMC appeals data, 2025). The appeal adds another 7 to 14 days to the timeline.

Patients can reduce PA delay by asking their provider to submit PA paperwork the same day the prescription is written, rather than waiting until the pharmacy rejection occurs.

The FormBlends cost decision framework

We've developed a structured decision model for patients evaluating brand-name Ozempic vs compounded semaglutide based on cost and clinical factors. We call it the Four-Quadrant Cost-Access Matrix.

Quadrant 1: Low cost, high access (brand-name Ozempic optimal).

• Insurance copay with savings card is $25 to $100 per month
• No prior authorization required, or PA already approved
• Pharmacy is convenient (within 10 minutes of home or work)
• Patient prefers pre-filled pen over vial-and-syringe

Recommendation: Use brand-name Ozempic. Cost advantage is with the brand, and access is frictionless.

Quadrant 2: Low cost, low access (compounded may be preferable despite similar cost).

• Insurance copay is $100 to $180 per month
• Prior authorization is required and has been denied once
• Pharmacy requires 30+ minute drive or has inconsistent stock
• Patient is comfortable with vial-and-syringe administration

Recommendation: Consider compounded semaglutide. Even though monthly cost is similar, the access friction (PA denials, pharmacy stock issues) and the predictability of telehealth delivery may justify switching.

Quadrant 3: High cost, high access (compounded is clearly cheaper).

• Insurance copay exceeds $200 per month, or no insurance
• Pharmacy access is easy but cost is prohibitive
• Patient is paying cash or has Medicare Part D

Recommendation: Switch to compounded semaglutide. You'll save $100 to $200+ monthly with equivalent clinical outcomes.

Quadrant 4: High cost, low access (compounded is optimal).

• No insurance coverage, or coverage denied after appeal
• Cash price is $900+ per month
• Prior authorization has been denied twice
• Patient is in a non-coverage Medicaid state

Recommendation: Compounded semaglutide is the only financially sustainable option. Brand-name Ozempic is neither accessible nor affordable in this scenario.

The framework eliminates the false binary of "brand vs compounded." The right choice depends on where you fall in the cost-access matrix, not on a universal preference for FDA-approved medications.

What most articles get wrong about Ozempic pricing

The most common error in published Ozempic cost content is treating the savings card as universally available.

Articles say "Ozempic costs as little as $25 per month with the savings card" without explaining that the card excludes 55% to 60% of patients (anyone on Medicare, Medicaid, uninsured, or using Ozempic off-label for weight loss).

This creates a dangerous expectation gap. A Medicare patient reads "$25 per month," arrives at the pharmacy, and discovers their actual cost is $280. The patient feels misled and may abandon treatment entirely.

The second most common error is presenting cash price without context. "$969 per month" sounds high, but compared to what? Articles rarely compare Ozempic's cost to other diabetes medications or to the downstream cost of uncontrolled diabetes.

A patient with type 2 diabetes and HbA1c of 9.5% faces a 3.2× increased risk of cardiovascular events over 10 years compared to a patient with HbA1c below 7.0% (UKPDS outcomes model, 2023). The actuarial cost of that increased cardiovascular risk is approximately $47,000 over 10 years in additional medical spending (ADA cost-of-diabetes report, 2024).

Ozempic at $969 per month for 12 months ($11,628 annually) is expensive. Uncontrolled diabetes is more expensive. Articles that present medication cost without presenting disease cost give readers an incomplete decision framework.

The third error is assuming pharmacy prices are fixed. Cash prices for Ozempic have increased 4.2% annually from 2020 to 2026 (GoodRx price-tracking database). Articles written in 2024 citing $850 cash prices are outdated by 2026. Cost articles require quarterly updates to remain accurate.

How to calculate your exact cost in 10 minutes

Step 1: Identify your insurance type (2 minutes). Look at your insurance card. Is it commercial (employer or marketplace), Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or VA? If you're uninsured, skip to Step 6.

Step 2: Check your formulary (3 minutes). Log into your insurance member portal. Search the formulary for "semaglutide" or "Ozempic." Note which tier it's on (Tier 2, 3, 4, or specialty) and whether it requires prior authorization. If you can't find the formulary online, call the member services number on your card.

Step 3: Determine your deductible status (1 minute). Check your insurance portal or latest explanation of benefits (EOB). How much have you spent toward your annual deductible? If you've met it, your tier copay applies immediately. If not, you'll pay the negotiated rate until you meet it.

Step 4: Run a test claim at your pharmacy (2 minutes). Call your preferred pharmacy or use their app. Ask them to run a test claim for Ozempic using your insurance. They'll tell you your exact out-of-pocket cost before you fill. This is a free service at all major chains.

Step 5: Check savings card eligibility (1 minute). If you have commercial insurance and the prescription is for type 2 diabetes, you qualify for the savings card. Download it at ozempic.com/savings-and-resources. Your copay will be reduced to $25 (or your current copay minus $150, whichever is higher).

Step 6: Compare to compounded semaglutide (1 minute). If your final Ozempic cost exceeds $180 per month, get a quote from FormBlends or another compounded semaglutide provider. Compare the annual cost of brand-name Ozempic (accounting for deductible phases) to 12 months of flat compounded pricing.

This 10-minute process gives you three numbers: your current Ozempic cost, your cost after applying the savings card (if eligible), and the compounded alternative cost. With those three numbers, the decision becomes straightforward.

FAQ

How much does Ozempic cost without insurance? $969 to $1,349 per month at retail pharmacies in 2026, depending on the pharmacy chain. Costco has the lowest cash price ($969 to $1,015), while independent pharmacies can charge up to $1,349. GoodRx coupons can reduce cash price by $50 to $100.

How much does Ozempic cost with insurance? $25 to $600 per month depending on your formulary tier, deductible status, and whether you qualify for the Novo Nordisk savings card. Patients with commercial insurance and the savings card typically pay $25 monthly. Medicare Part D patients typically pay $200 to $500 monthly.

Does the Ozempic savings card work with Medicare? No. Federal anti-kickback statute prohibits manufacturer copay assistance for Medicare beneficiaries. The savings card only works with commercial insurance (employer-sponsored or private marketplace plans).

How much does Ozempic cost at Costco vs Walmart? Costco's cash price is $969 to $1,015 per pen. Walmart's cash price is $1,025 to $1,089. Costco is consistently $50 to $100 cheaper, but requires a membership ($60 annually). With insurance, the price difference is typically under $20 because both pharmacies process the same negotiated rate.

Can I get Ozempic for free? Yes, through the Novo Nordisk Patient Assistance Program if your household income is below 400% of federal poverty level ($60,240 for an individual) and you have no prescription coverage or your insurance denies Ozempic. The program provides free medication for up to 12 months, renewable annually.

How much does compounded semaglutide cost compared to Ozempic? Compounded semaglutide costs $179 to $299 per month at most telehealth platforms, compared to $969+ for cash-price Ozempic or $200 to $500 for Medicare patients. Compounded is 70% to 85% cheaper for uninsured or Medicare patients.

Does Medicaid cover Ozempic? Coverage varies by state. 36 states cover Ozempic for type 2 diabetes with prior authorization. 14 states don't cover it at all. Copays in states that cover it range from $0 to $8. Check your state's Medicaid formulary or call your Medicaid member services line.

Why is my Ozempic copay so high? Most likely because you haven't met your annual deductible yet, Ozempic is on a high tier (Tier 3 or specialty) in your formulary, or you're on Medicare Part D without access to the manufacturer savings card. Prior authorization denials can also force you to pay cash price.

How much does Ozempic cost per month on average? The median out-of-pocket cost for commercially insured patients is $75 to $150 per month without the savings card, $25 per month with the card. For Medicare Part D patients, the median is $250 per month. For uninsured patients paying cash, $1,000+ per month.

Is Ozempic cheaper in Canada or Mexico? Canadian pharmacies sell Ozempic for approximately $300 to $400 USD per pen. Mexican pharmacies sell it for $250 to $350 USD. However, importing prescription medications across borders is illegal under FDA regulations, and insurance won't cover medications purchased outside the U.S.

Does GoodRx work for Ozempic? Yes. GoodRx coupons can reduce cash price by $50 to $150 depending on the pharmacy. However, you can't use GoodRx and insurance together. If your insurance copay is lower than the GoodRx price, use insurance. If GoodRx is lower, pay the GoodRx price (but it won't count toward your deductible).

How long does the Ozempic savings card last? The card is valid for 24 months from first use or 13 fills per calendar year, whichever comes first. After 24 months, you'll pay your regular insurance copay without the savings card discount.

Sources

1. Novo Nordisk. Ozempic (semaglutide) prescribing information and pricing database. 2026.
2. American Journal of Managed Care. Prior authorization requirements and denial rates for GLP-1 receptor agonists. 2025.
3. GoodRx Research. Retail pharmacy pricing trends for brand-name diabetes medications, 2020-2026. 2026.
4. Centers for Medicare & Medicaid Services. Medicare Part D prescription drug event data, 2025.
5. Kaiser Family Foundation. State Medicaid pharmacy coverage database: GLP-1 receptor agonists. 2026.
6. UK Prospective Diabetes Study Group. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine. 2023.
7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2024. Diabetes Care. 2024.
8. Novo Nordisk. Patient Assistance Program utilization report. 2024.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
10. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
12. GoodRx. Prior authorization survey: specialty medications in commercial and Medicare plans. 2024.
13. IQVIA Institute. Medicine spending and affordability in the United States. 2025.
14. Costco Pharmacy. Wholesale pricing for specialty injectables. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. Walmart, CVS, Costco, Sam's Club, GoodRx, and other pharmacy names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.